DFTX- Definium Therapeutics, Inc.

Over the past 90 days, insiders at Definium Therapeutics, Inc. (DFTX) have been net sellers, shedding 81,951 shares worth roughly $3.0M on balance.

DFTX sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Barrow Robert	2.21M	$80.93M	-
Other	Karlin Daniel	792.8K	$28.99M	-
Other	Sullivan Mark	494.2K	$18.07M	-
CFO	Roberts Brandi	394.5K	$14.43M	-
Other	Wiley Matthew T.	359.0K	$13.13M	-

Buys and sells only

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Sep 25, 2026	Wiley Matthew T.82	Chief Commercial Officer	Sell	3,097	$36.57	$113,257.29	-0.9%	-	-
Sep 25, 2026	Sullivan Mark	Chief Legal Officer	Sell	14,051	$36.57	$513,845.07	-2.8%	-	-
Sep 25, 2026	Karlin Daniel	Chief Medical Officer	Sell	10,853	$36.57	$396,894.21	-1.4%	-	-
Sep 25, 2026	Barrow Robert	Chief Executive Officer	Sell	31,550	$36.57	$1,153,783.50	-1.4%	-	-
Sep 25, 2026	Roberts Brandi	Chief Financial Officer	Sell	3,377	$36.57	$123,496.89	-0.8%	-	-
Sep 3, 2026	Barrow Robert	Chief Executive Officer	Sell	19,023	$37.94	$721,732.62	-1.3%	-	-
Jun 25, 2026	Wiley Matthew T.82	Chief Commercial Officer	Sell	2,867	$45.03	$129,101.01	-1.6%	-15.9%	-
Jun 25, 2026	Sullivan Mark	Chief Legal Officer	Sell	13,008	$45.03	$585,750.24	-3.9%	-15.9%	-
Jun 25, 2026	Karlin Daniel	Chief Medical Officer	Sell	10,035	$45.03	$451,876.05	-2.0%	-15.9%	-
Jun 25, 2026	Roberts Brandi	Chief Financial Officer	Sell	3,013	$45.03	$135,675.39	-1.4%	-15.9%	-